drug · antibody
patient view →crovalimab
Phase 3updated 2mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for paroxysmal nocturnal hemoglobinuria and 4 investigational indications.
targets
Complement C5
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that